Complaints Outcomes

Search

Search Results

Search Again
Pharmacist Registrant 37 (Oct 15, 2019)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on June 25, 2018. Pursuant to section 32.2(4)(b)(i) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to:

  1. The Registrant will adhere to routine medical monitoring program with the institution currently involved in the Registrant’s case and remain on the program for two years;

  2. In the event of any interruption to the agreed monitoring schedule set out by the medical monitoring program, the Registrant will advise the College of the interruption as soon as possible and provide an explanation for the interruption; and

  3. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in the Registrant’s care.  

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purpose of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


June 25, 2018
(October 15, 2019 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with pharmacist registrant to suspend registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pharmacist Registrant 42 (Aug 14, 2019)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective August 14, 2019. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pharmacist Registrant 31 (Jul 19, 2019)

Pharmacist registrant 31 has satisfied the terms of an Agreement reached with the Inquiry Committee on August 22, 2017. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


August 22, 2017
(July 19, 2019 - Limits and conditions removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on March 20, 2017. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to:

  1. The Registrant will adhere to routine medical monitoring program with the institution currently involved in the Registrant’s case and remain on the monitoring program for three years;

  2. The Registrant will not work alone in a pharmacy, and will, at all times, have another pharmacist or pharmacy technician/assistant/staff on site at all times;

  3. The Registrant will not have any access whatsoever, on or off-duty, to the narcotic safe in any pharmacy;

  4. The Registrant will not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

  5. The Registrant will not dispense own medications;

  6. The Registrant shall disclose to the pharmacy manager/or employer the limits and conditions on the Registrant’s license pursuant to the agreement prior to the commencement of new employment at any pharmacy;

  7. The Registrant will ensure that the pharmacy manager and/or employer with whom the Registrant secures employment submits a written statement to the College declaring their awareness of the Registrant’s medical condition and the agreement;

  8. The Registrant will notify the College, in writing or via e-mail, of places of employment as a pharmacist and report any changes to the location of employment within 48 hours of such change. A reportable change to the Registrant’s place of employment contemplates both commencement and termination of employment;

  9. The Registrant will be restricted from acting in the following roles in the Registrant’s practice:

    • Be a manager of a pharmacy;
    • Be a director of a corporation that owns a pharmacy; and
    • Act as a preceptor.

     

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


March 20, 2017
(AugUst 22, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement by consent with the pharmacist registrant to voluntarily suspend registration as a pharmacist effective March 20, 2017. The agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Pharmacist Registrant 41 (Jul 3, 2019)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective July 3, 2019. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Tejani, Diamondali Alladin (Jun 20, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted an investigation into the practice of Diamondali Alladin Tejani (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183.

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: June 20, 2019

  3. Name of registrant: Diamondali Alladin Tejani

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgements:

    Between July 8, 2016 and November 25, 2016, while he was owner, manager and pharmacist, several pharmacy practice deficiencies were identified. The Registrant has admitted and/or acknowledged the following:

    1. Pharmacy staff provided cash incentives in exchange for daily dispense prescriptions;

    2. He knew or should have known that a pharmacist/patient consultation was required for new and refill daily dispense prescriptions;
       
    3. On several occasions, pharmacy staff entered and did not reverse daily dispense prescriptions on PharmaNet when the patient did not attend the pharmacy;

    4. Pharmacy staff dispensed several prescriptions contrary to the prescriber’s instructions (by providing missed doses for a prescription that was required to be daily dispensed); and
       
    5. Pharmacy staff dispensed several prescriptions without prescription labels.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee of CPBC, wherein the Registrant consented to the following terms (in part):

    1. To suspend his registration as a pharmacist for 180 consecutive days commencing September 18, 2019.

    2. To not be a pharmacy manager, director, owner (direct or indirect), shareholder in a corporation that owns a pharmacy and preceptor for a period of two years from the date that his suspension ends;
       
    3. At his own costs, to complete and pass an ethics course for healthcare professionals; and

    4. To pay a $15,000.00 fine.
       
  7. Rationale:

    The Inquiry Committee determined that the totality of the Registrant’s past and present conduct raised serious concerns about his ethical and professional standards in the course of his practice at the pharmacy as a pharmacist, pharmacy manager and owner. The Inquiry Committee determined that his poor standard of practice warranted limits and conditions imposed on his licence, in addition to a fine and a requirement to take an ethics course in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. 

Khun-Khun, Amandeep Singh (Jun 12, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the practice of now former registrant Amandeep Singh Khun-Khun (the “Former Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Former Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: June 12, 2019

  3. Name of registrant: Amandeep Singh Khun-Khun

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgements:

    Between January 1, 2014 and November 5, 2017, over 15,000 transactions for over-the-counter (“OTC”) and/or vitamin products were processed on a daily or weekly basis on the PharmaNet records of seven individuals. These seven individuals were not prescribed and had not received any of the OTC and/or vitamin products processed on their PharmaNet records. Most of the seven individuals stated that they had not willingly consented to having these transactions on their PharmaNet records.

    These transactions all originated from a pharmacy where the Former Registrant was the pharmacy manager and owner.

    The Former Registrant admitted that he had directed pharmacy assistants to process transactions weekly on PharmaNet in order to artificially inflate the pharmacy’s prescription count. The pharmacy assistants used the registration numbers of various pharmacist registrants as the dispensing pharmacist and/or prescriber for each transaction. The majority of pharmacy registrants stated that their registration numbers were used without their willing consent or knowledge. Many of these transactions were also backdated.

    The Former Registrant’s actions and direction enabled the inappropriate access and use of PharmaNet records, enabled the inappropriate access and use of pharmacist registration numbers, and caused PharnaNet records to be inaccurate and not current.

  6. Disposition:

    The Former Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Former Registrant consented to the following terms: 

    1. To suspend his registration as a pharmacist for a total of 540 days, to commence upon his reinstatement to Full Pharmacist status;

    2. To not be a pharmacy manager, director, owner (direct or indirect), shareholder, and preceptor for pharmacy students for a period of five years from the date that his suspension ends;
       
    3. To successfully pass the College’s Jurisprudence Exam;

    4. To successfully complete and pass an ethics course for healthcare professionals; and.

    5. To pay a $30,000.00 fine.

  7. Rationale:

    The Inquiry Committee considered that the Former Registrant’s intentional directing of weekly transactions which enabled the processing of over 15,000 false prescriptions on PharmaNet involved significant breaches of confidentiality and trust. The fact that his actions led to an inflated prescription count, from which the Inquiry Committee believed he gained financial and personal benefit, made his conduct even more serious.

    His actions were considered serious contraventions of legislation involving use and protection of personal information, appropriate use and access of PharmaNet and patient records, supervision of pharmacy assistants, and his role as a pharmacy manager. He also contravened standards of the Code of Ethics involving protecting and promoting the well-being of patients, benefitting society, committing to personal and professional integrity, and participating in ethical business practices. The Inquiry Committee also considered that the Former Registrant had previously consented to remedial undertakings to fully comply with ethical requirements, and he had breached these undertakings for this current matter. The totality of the Former Registrant’s serious, intentional, and repeated conduct amounted to significant professional misconduct, and the Inquiry Committee considered that the Former Registrant required the above-referred-to remediation and deterrence in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. Inappropriate access and use of personal information, especially without consent, compromises the public’s trust in the pharmacy profession as a whole. At all times, registrants must uphold legislative requirements and ethical obligations to appropriately access, use, and protect personal information.

Ladha, Azizabegum (Jun 7, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“the College”) conducted an investigation into the practice of Azizabegum Ladha (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: June 7, 2019

  3. Name of registrant: Azizabegum Ladha 

  4. Location of Practice: Surrey, BC

  5. Admissions and Acknowledgements:

    Between January 2016 and July 2016, the Registrant worked at two different pharmacies, one of which she was the pharmacy manager. During this time, the following pharmacy practice issues and contraventions of legislation occurred, of which she had direct involvement:

    1. She did not provide adequate pharmacist/patient consultations for refill medications;

    2. She dispensed Schedule I medication in a manner that was not authorized in the prescriptions;

    3. She processed inaccurate and non-current transactions on PharmaNet;

    4. She did not review PharmaNet prior to dispensing prescriptions; and

    5. She did not take reasonable steps to confirm the identity of a patient before dispensing medication for this patient.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to the following terms:

    1. To suspend her registration as a pharmacist for a total of 30 consecutive days;

    2. To not be a pharmacy manager and preceptor for a period of 18 months from the date that her suspension ends;
       
    3. To pay a fine in the amount of $5,000.00; and

    4. To successfully complete and pass the “BC Pharmacy Manager Training Program” offered by the British Columbia Pharmacy Association.

  7. Rationale:

    The Inquiry Committee was concerned that the Registrant had previously consented to undertakings and a reprimand related to her pharmacy practice, from which she should have remediated. However, in this current matter she contravened practice standards which could have endangered patient health. The Inquiry Committee therefore considered the totality of the Registrant’s conduct to be serious, and that she required further remediation and deterrence in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession.

Sam, William Byron (Jun 6, 2019)

Pursuant to section 35(1)(b) of the Health Professions Act, the Inquiry Committee has ordered a suspension of the registration of registrant William Byron Sam pending completion of an investigation, effective June 6, 2019. The Registrant will not be able to practice pharmacy in the province of British Columbia while his registration is suspended. The Inquiry Committee considered the suspension necessary to protect the public.

The Inquiry Committee was satisfied on the information before it that there is a real risk to the public should this interim order not be put in place. The Registrant was knowingly operating an unlicensed pharmacy, contrary to the directions of the College. Serious public risk indicators were present within the pharmacy. The Registrant continued to display an inexplicable pattern of responsiveness to and disregard for the College and its regulatory requirements and its communications with him.

Note: Suspensions ordered by the Inquiry Committee under section 35(1)(b) of the Health Professions Act are made to protect the public during an investigation or pending a hearing of the Discipline Committee. Orders made under this section relate to matters which are and remain unproven unless admitted by a registrant or determined by the Discipline Committee.

Pharmacist Registrant 22 (Jun 5, 2019)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act and after consultation with the pharmacist registrant’s physician, has reached an Agreement with the pharmacist registrant to amend some of the terms in the Agreement of October 12, 2018. The Registrant can now:

  • work alone in a pharmacy;
  • handle, physically prepare, and dispense prescriptions for opioid medications;
  • have access to the narcotic safe;
  • be involved with ordering narcotic medications.

October 12, 2019
(June 5, 2019 - Limits and Conditions Updated)

The Inquiry Committee has reinstated the pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 13, 2015. Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To strictly adhere to the Registrant's routine medical monitoring program with the institution currently involved in the Registrant's care and remaining on the monitoring program for a period of at least 3 years;

  2. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in the Registrant's care;

  3. To not work alone in a pharmacy, and to have another pharmacist in good standing supervising the Registrant at all times;

  4. To not handle, physically prepare, or dispense prescriptions for opioid medications at any time;

  5. To not have any access whatsoever, on or off duty, to the narcotic safe in any pharmacy;

  6. To not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

  7. To inform all managers and employers with whom the Registrant gains employment of his medical condition and the limits and conditions on registration pursuant to the Agreement;

  8. To ensure that all managers and employers with whom the Registrant gains employment submits a written statement to the College declaring their awareness of the Registrant's medical condition and the Agreement, and how they will accommodate and supervise the Registrant working in the pharmacy;
     
  9. To inform the College in via e-mail of his places of employment as a pharmacist and report any changes to the location of his employment within 48 hours of such change; and

  10. To be restricted from acting in the following roles in the Registrant's practice:

    1. Be a manager of a pharmacy;
    2. Be an owner (direct or indirect) of a pharmacy; and
    3. Act as a preceptor.

     


August 13, 2015
(October 12, 2018 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend registration as a pharmacist effective August 13, 2015. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


February 13, 2015
(AUGUST 13, 2015 - Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 5, 2014. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Routine and random medical monitoring;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. Registrant will not be involved in the dispensing, ordering, contact, destruction, counting or otherwise handling of opiate medications and other medications with abusive potential;

  8. Being restricted from the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor.

     

  9. Notifying the College of:

    1. all changes in places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

     

The Agreement will remain in place for a minimum of three years of continuous pharmacy practice. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public. 


August 5, 2014
(February 13, 2015 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend registration as a pharmacist effective August 5, 2014. The Agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Tam, Sing Man (May 27, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the practice of Sing Man Tam (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: May 27, 2019

  3. Name of registrant: Sing Man Tam​

  4. Admissions and Acknowledgements:

    On October 13, 2015, the College received correspondence from the BC Ministry of Health regarding potential pharmacy practice concerns at the Pharmacy, arising from a PharmaCare Audit of the Pharmacy that covered the time period between September 1, 2012 and August 31, 2014 (the “Audit Period”).  Further to the College’s investigation of those practice concerns, the Registrant acknowledged

    1. prescriptions were missing date or quantity to dispense,

    2. prescriptions were filled under the incorrect prescriber,
       
    3. a prescription was dispensed for the wrong dose,

    4. prescriptions were written by the prescriber as daily witness ingestion but were processed under the Drug Identification Number (“DIN”) for methadone given without direct interaction
       
    5. a prescription was written by the physician for daily witness ingestion but was processed under the DIN for delivery of methadone, without authorization,

    6. medication reviews were submitted to PharmaNet that did not have any supporting documentation,

    7. prescriptions for Hepatitis C medications were not submitted to PharmaNet on the day of claimed dispense,
       
    8. prescriptions were written by the physician as daily dispense, but were filled and submitted to PharmaNet as a 7 days’ supply, with no documentation of a prescriber’s authorization to do so,

    9. a prescription was filled as a verbal authorization with incomplete documentation,

    10. a methadone prescription was billed on a day marked as “missed” on the ingestion logs,

    11. a prescription adaptation was conducted without adequate documentation,

    12. a methadone prescription did not have a part fill accountability log, and

    13. a methadone prescription was provided as delivery without prescriber authorization.

  5. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to the following terms:

    1. having a Letter of Reprimand placed permanently on his registration record;

    2. payment of a fine in the amount of $10,000;
       
    3. an undertaking to:

      1. not repeat the conduct to which this matter relates,
         
      2. thoroughly review and read legislation, standards and policies relevant to the conduct to which this matter relates, and thereafter submit a Declaration of Understanding regarding the legislation, standards and policies reviewed and read,
         
      3. complete the BC Pharmacy Manager Training Course as well as coursework relating to opioid agonist therapy,
         
      4. successfully complete the College’s Jurisprudence Exam,
         
      5. at all times prior to completing the BC Pharmacy Manager Training Course and successfully completing the College’s Jurisprudence Exam only provide the services of a pharmacist when a least one other full pharmacist registrant is present with him in the pharmacy, and
         
      6. at all times after delivering the Declaration of Understanding, completing the BC Pharmacy Manager Training Course and coursework relating to methadone maintenance treatment, and successfully completing the College’s Jurisprudence Exam, be knowledgeable of and abide by all legislation and policy governing the practice of pharmacy.

       

  6. Rationale:

    The Inquiry Committee considered that in this case, the cumulative weight of the practice deficiencies demonstrated inadequate diligence and oversight in the Registrant’s practice, noting that many of the substantiated practice deficiencies were substantive, and not simply administrative. Accurate record keeping and documentation are fundamental to providing safe pharmaceutical care. Therefore, the Committee considered the Registrant’s conduct to be serious, and that the Registrant required both remediation and deterrence in order to come into compliance. The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession.

Pages